搜索结果：Veterinary and comparative oncology

Randomized discontinuation design (RDD) is an enrichment strategy commonly used to address limitations of traditional placebo-controlled trials, particularly the ethical concern of prolonged placebo exposure. RDD consists of two phases: an initial open-label phase in which all eligible patients receive the investigational medicinal product (IMP), followed by a double-blind phase in which responders are randomized to continue with the IMP or switch to placebo. This design tests whether the IMP provides benefit beyond the placebo effect. The estimand framework introduced in ICH E9(R1) strengthens the dialogue among clinical research stakeholders by clarifying trial objectives and aligning them with appropriate statistical analyses. However, its application in oncology trials using RDD remains unclear. This manuscript uses the phase III JAVELIN Gastric 100 trial and the phase II trial of sorafenib (BAY 43-9006) as case studies to propose an estimand framework tailored for oncology trials employing RDD in phase III and phase II settings, respectively. We highlight some similarities and differences between RDDs and traditional randomized controlled trials in the context of ICH E9(R1). T

Phase I dose escalation trials in oncology generally aim to find the maximum tolerated dose (MTD). However, with the advent of molecular targeted therapies and antibody drug conjugates, dose limiting toxicities are less frequently observed, giving rise to the concept of optimal biological dose (OBD), which considers both efficacy and toxicity. The Estimand framework presented in the addendum of the ICH E9(R1) guidelines strengthens the dialogue between different stakeholders by bringing in greater clarity in the clinical trial objectives and by providing alignment between the targeted estimand under consideration and the statistical analysis methods. However, there lacks clarity in implementing this framework in early phase dose optimization studies. This manuscript aims at discussing the Estimand framework for dose optimization trials in oncology considering efficacy and toxicity through utility functions. Such trials should include Pharmacokinetics (PK) data, toxicity data, and efficacy data. Based on these data, the analysis methods used to identify the optimized dose/s are also described. Focusing on optimizing the utility function to estimate the OBD, the population-level summ

Accurate trend forecasting in healthcare time series is essential for planning and resource allocation. This paper proposes a Bayesian framework for predicting oncology demand trends, modeling weekly appointments as a Poisson process with a Gamma prior to the demand rate. To enhance adaptability and capture persistent directional patterns, we incorporate a residual-based boosting mechanism grounded in a Gamma-Log-Normal conjugate structure. This boosting approach allows the model to track both short- and long-term trend shifts while maintaining the analytical tractability of conjugate Bayesian updating. The methodology was evaluated on real oncology service data from Cariri, Ceara, Brazil, and compared against established baselines, including linear regression, ARIMA, naive forecasting, LSTM neural networks, and XGBoost. Results showed that the proposed model outperforms competing methods in trend detection accuracy, with gains in terms of percentage of correct direction of 38.25% in relation to the second best approach in some cases.

Cancer evolves continuously over time through a complex interplay of genetic, epigenetic, microenvironmental, and phenotypic changes. This dynamic behavior drives uncontrolled cell growth, metastasis, immune evasion, and therapy resistance, posing challenges for effective monitoring and treatment. However, today's data-driven research in oncology has primarily focused on cross-sectional analysis using data from a single modality, limiting the ability to fully characterize and interpret the disease's dynamic heterogeneity. Advances in multiscale data collection and computational methods now enable the discovery of longitudinal multimodal biomarkers for precision oncology. Longitudinal data reveal patterns of disease progression and treatment response that are not evident from single-timepoint data, enabling timely abnormality detection and dynamic treatment adaptation. Multimodal data integration offers complementary information from diverse sources for more precise risk assessment and targeting of cancer therapy. In this review, we survey methods of longitudinal and multimodal modeling, highlighting their synergy in providing multifaceted insights for personalized care tailored to

Clinical oncology generates vast, unstructured data that often contain inconsistencies, missing information, and ambiguities, making it difficult to extract reliable insights for data-driven decision-making. General-purpose large language models (LLMs) struggle with these challenges due to their lack of domain-specific reasoning, including specialized clinical terminology, context-dependent interpretations, and multi-modal data integration. We address these issues with an oncology-specialized, efficient, and adaptable NLP framework that combines instruction tuning, retrieval-augmented generation (RAG), and graph-based knowledge integration. Our lightweight models prove effective at oncology-specific tasks, such as named entity recognition (e.g., identifying cancer diagnoses), entity linking (e.g., linking entities to standardized ontologies), TNM staging, document classification (e.g., cancer subtype classification from pathology reports), and treatment response prediction. Our framework emphasizes adaptability and resource efficiency. We include minimal German instructions, collected at the University Hospital Zurich (USZ), to test whether small amounts of non-English language dat

Mathematical oncology is an interdisciplinary research field where the mathematical sciences meet cancer research. Being situated at the intersection of these two fields makes mathematical oncology highly dynamic, as practicing researchers are incentivised to quickly adapt to both technical and medical research advances. Determining the scope of mathematical oncology is therefore not straightforward; however, it is important for purposes related to funding allocation, education, scientific communication, and community organisation. To address this issue, we here conduct a bibliometric analysis of mathematical oncology. We compare our results to the broader field of mathematical biology, and position our findings within theoretical science of science frameworks. Based on article metadata and citation flows, our results provide evidence that mathematical oncology has undergone a significant evolution since the 1960s marked by increased interactions with other disciplines, geographical expansion, larger research teams, and greater diversity in studied topics. The latter finding contributes to the greater discussion on which models different research communities consider to be valuable

Heart disease is among the most common serious conditions in dogs and cats, and a heart murmur heard on auscultation is one of the earliest signs of such disease; such murmurs are often subtle and challenging to detect at early stages. General-practice veterinary examinations catch only a fraction of these murmurs, and definitive cardiac assessment typically requires either a board-certified cardiologist or an in-clinic echocardiogram, which may involve cost and scheduling constraints. We describe Sonus Health, a smartphone-based screening system that analyses an auscultation recording of approximately thirty seconds or longer - captured by a pet owner at home or by a veterinarian or nurse in clinic - and returns a tiered result within moments. The system was evaluated on 322 veterinary-labelled recordings under standard out-of-fold cross-validation. For recordings assigned to the high-confidence tier (30% of cases), accuracy reaches 95.9%, with 94.0% sensitivity and 97.9% specificity. Uncertain cases are prospectively routed to veterinary review rather than assigned an automated classification. Results are stable across standard and group-aware cross-validation, a held-out test sp

Thanks to the rapidly evolving integration of LLMs into decision-support tools, a significant transformation is happening across large-scale systems. Like other medical fields, the use of LLMs such as GPT-4 is gaining increasing interest in radiation oncology as well. An attempt to assess GPT-4's performance in radiation oncology was made via a dedicated 100-question examination on the highly specialized topic of radiation oncology physics, revealing GPT-4's superiority over other LLMs. GPT-4's performance on a broader field of clinical radiation oncology is further benchmarked by the ACR Radiation Oncology In-Training (TXIT) exam where GPT-4 achieved a high accuracy of 74.57%. Its performance on re-labelling structure names in accordance with the AAPM TG-263 report has also been benchmarked, achieving above 96% accuracies. Such studies shed light on the potential of LLMs in radiation oncology. As interest in the potential and constraints of LLMs in general healthcare applications continues to rise5, the capabilities and limitations of LLMs in radiation oncology decision support have not yet been fully explored.

Large language models (LLMs) are increasingly used in clinical settings, yet their performance in veterinary medicine remains underexplored. We evaluated three commercially available veterinary-focused LLM summarization tools (Product 1 [Hachiko] and Products 2 and 3) on a standardized dataset of veterinary oncology records. Using a rubric-guided LLM-as-a-judge framework, summaries were scored across five domains: Factual Accuracy, Completeness, Chronological Order, Clinical Relevance, and Organization. Product 1 achieved the highest overall performance, with a median average score of 4.61 (IQR: 0.73), compared to 2.55 (IQR: 0.78) for Product 2 and 2.45 (IQR: 0.92) for Product 3. It also received perfect median scores in Factual Accuracy and Chronological Order. To assess the internal consistency of the grading framework itself, we repeated the evaluation across three independent runs. The LLM grader demonstrated high reproducibility, with Average Score standard deviations of 0.015 (Product 1), 0.088 (Product 2), and 0.034 (Product 3). These findings highlight the importance of veterinary-specific commercial LLM tools and demonstrate that LLM-as-a-judge evaluation is a scalable and

Self-supervised learning has emerged as a powerful paradigm for training deep neural networks, particularly in medical imaging where labeled data is scarce. While current approaches typically rely on synthetic augmentations of single images, we propose VET-DINO, a framework that leverages a unique characteristic of medical imaging: the availability of multiple standardized views from the same study. Using a series of clinical veterinary radiographs from the same patient study, we enable models to learn view-invariant anatomical structures and develop an implied 3D understanding from 2D projections. We demonstrate our approach on a dataset of 5 million veterinary radiographs from 668,000 canine studies. Through extensive experimentation, including view synthesis and downstream task performance, we show that learning from real multi-view pairs leads to superior anatomical understanding compared to purely synthetic augmentations. VET-DINO achieves state-of-the-art performance on various veterinary imaging tasks. Our work establishes a new paradigm for self-supervised learning in medical imaging that leverages domain-specific properties rather than merely adapting natural image techniq

ChatGPT, the most accessible generative artificial intelligence (AI) tool, offers considerable potential for veterinary medicine, yet a dedicated review of its specific applications is lacking. This review concisely synthesizes the latest research and practical applications of ChatGPT within the clinical, educational, and research domains of veterinary medicine. It intends to provide specific guidance and actionable examples of how generative AI can be directly utilized by veterinary professionals without a programming background. For practitioners, ChatGPT can extract patient data, generate progress notes, and potentially assist in diagnosing complex cases. Veterinary educators can create custom GPTs for student support, while students can utilize ChatGPT for exam preparation. ChatGPT can aid in academic writing tasks in research, but veterinary publishers have set specific requirements for authors to follow. Despite its transformative potential, careful use is essential to avoid pitfalls like hallucination. This review addresses ethical considerations, provides learning resources, and offers tangible examples to guide responsible implementation. Carefully selected, up-to-date lin

Veterinary medical records represent a large data resource for application to veterinary and One Health clinical research efforts. Use of the data is limited by interoperability challenges including inconsistent data formats and data siloing. Clinical coding using standardized medical terminologies enhances the quality of medical records and facilitates their interoperability with veterinary and human health records from other sites. Previous studies, such as DeepTag and VetTag, evaluated the application of Natural Language Processing (NLP) to automate veterinary diagnosis coding, employing long short-term memory (LSTM) and transformer models to infer a subset of Systemized Nomenclature of Medicine - Clinical Terms (SNOMED-CT) diagnosis codes from free-text clinical notes. This study expands on these efforts by incorporating all 7,739 distinct SNOMED-CT diagnosis codes recognized by the Colorado State University (CSU) Veterinary Teaching Hospital (VTH) and by leveraging the increasing availability of pre-trained language models (LMs). 13 freely-available pre-trained LMs were fine-tuned on the free-text notes from 246,473 manually-coded veterinary patient visits included in the CSU

The essence of precision oncology lies in its commitment to tailor targeted treatments and care measures to each patient based on the individual characteristics of the tumor. The inherent heterogeneity of tumors necessitates gathering information from diverse data sources to provide valuable insights from various perspectives, fostering a holistic comprehension of the tumor. Over the past decade, multimodal data integration technology for precision oncology has made significant strides, showcasing remarkable progress in understanding the intricate details within heterogeneous data modalities. These strides have exhibited tremendous potential for improving clinical decision-making and model interpretation, contributing to the advancement of cancer care and treatment. Given the rapid progress that has been achieved, we provide a comprehensive overview of about 300 papers detailing cutting-edge multimodal data integration techniques in precision oncology. In addition, we conclude the primary clinical applications that have reaped significant benefits, including early assessment, diagnosis, prognosis, and biomarker discovery. Finally, derived from the findings of this survey, we presen

Large language models (LLMs) can extract information from veterinary electronic health records (EHRs), but performance differences between models, the effect of temperature settings, and the influence of text ambiguity have not been previously evaluated. This study addresses these gaps by comparing the performance of GPT-4 omni (GPT-4o) and GPT-3.5 Turbo under different conditions and investigating the relationship between human interobserver agreement and LLM errors. The LLMs and five humans were tasked with identifying six clinical signs associated with Feline chronic enteropathy in 250 EHRs from a veterinary referral hospital. At temperature 0, the performance of GPT-4o compared to the majority opinion of human respondents, achieved 96.9% sensitivity (interquartile range [IQR] 92.9-99.3%), 97.6% specificity (IQR 96.5-98.5%), 80.7% positive predictive value (IQR 70.8-84.6%), 99.5% negative predictive value (IQR 99.0-99.9%), 84.4% F1 score (IQR 77.3-90.4%), and 96.3% balanced accuracy (IQR 95.0-97.9%). The performance of GPT-4o was significantly better than that of its predecessor, GPT-3.5 Turbo, particularly with respect to sensitivity where GPT-3.5 Turbo only achieved 81.7% (IQR

Mechanistic learning, the synergistic combination of knowledge-driven and data-driven modeling, is an emerging field. In particular, in mathematical oncology, the application of mathematical modeling to cancer biology and oncology, the use of mechanistic learning is growing. This review aims to capture the current state of the field and provide a perspective on how mechanistic learning may further progress in mathematical oncology. We highlight the synergistic potential of knowledge-driven mechanistic mathematical modeling and data-driven modeling, such as machine and deep learning. We point out similarities and differences regarding model complexity, data requirements, outputs generated, and interpretability of the algorithms and their results. Then, organizing combinations of knowledge- and data-driven modeling into four categories (sequential, parallel, intrinsic, and extrinsic mechanistic learning), we summarize a variety of approaches at the interface between purely data- and knowledge-driven models. Using examples predominantly from oncology, we discuss a range of techniques including physics-informed neural networks, surrogate model learning, and digital twins. We see that m

Personalized oncology aims to tailor treatment strategies to the unique molecular and clinical profiles of individual patients, moving beyond the traditional paradigm of treating the disease not the patient. Achieving this vision requires the integration and interpretation of vast, heterogeneous biomedical data within a meaningful scientific framework. Knowledge graphs, structured according to biomedical ontologies, offer a powerful approach to contextualize and interconnect diverse datasets, enabling more precise and informed clinical decision-making. We present ECKO (Explainable Clinical Knowledge for Oncology), a comprehensive knowledge graph that integrates 33 biomedical ontologies and aggregates data from multiple studies to create a unified resource optimized for data-driven clinical applications in oncology. Designed to support personalized drug recommendations, ECKO facilitates the identification of optimal therapeutic options by linking patient-specific molecular data to relevant pharmacological knowledge. It provides transparent, interpretable explanations for drug recommendations, fostering greater trust and understanding among clinicians and researchers. This resource r

In the past year, there has been a growing trend in applying Large Language Models (LLMs) to the field of medicine, particularly with the advent of advanced language models such as ChatGPT developed by OpenAI. However, there is limited research on LLMs specifically addressing oncology-related queries. The primary aim of this research was to develop a specialized language model that demonstrates improved accuracy in providing advice related to oncology. We performed an extensive data collection of online question-answer interactions centered around oncology, sourced from reputable doctor-patient platforms. Following data cleaning and anonymization, a dataset comprising over 180K+ oncology-related conversations was established. The conversations were categorized and meticulously reviewed by field specialists and clinicians to ensure precision. Employing the LLaMA model and other selected open-source datasets, we conducted iterative fine-tuning to enhance the model's proficiency in basic medical conversation and specialized oncology knowledge. We observed a substantial enhancement in the model's understanding of genuine patient inquiries and its reliability in offering oncology-relate

Cancer is a complex genetic disease involving uncontrolled cell growth and proliferation, and necessitates effective targeting of dysregulated cellular pathways underlying cancer progression. Multiple genetic and epigenetic alterations characterize tumor progression and define hallmarks of cancer. Importantly, patients with the same cancer type respond differently to available cancer treatments, likely due to tumor-specific DNA, RNA, and proteins, indicating the need for patient-specific treatment options. Precision oncology has evolved as a form of cancer therapy that is focused on genetic and molecular profiling of tumors to identify specific molecular alterations involved in carcinogenesis for tailored individualized cancer treatment. Advances in high-throughput sequencing technologies have enabled gene expression profiling, providing multiomics data for detailed molecular characterization of various tumors. Integration and analysis of various multiomic sequencing data are crucial in this regard, as they can reveal critical molecular changes, such as cancer-driving mutations, post-translational modifications, gene fusions, amplifications, and alterations in signaling networks wi

COVID-19 outbreak has rapidly evolved into a global pandemic. The impact of COVID-19 on patient journeys in oncology represents a new risk to interpretation of trial results and its broad applicability for future clinical practice. We identify key intercurrent events that may occur due to COVID-19 in oncology clinical trials with a focus on time-to-event endpoints and discuss considerations pertaining to the other estimand attributes introduced in the ICH E9 addendum. We propose strategies to handle COVID-19 related intercurrent events, depending on their relationship with malignancy and treatment and the interpretability of data after them. We argue that the clinical trial objective from a world without COVID-19 pandemic remains valid. The estimand framework provides a common language to discuss the impact of COVID-19 in a structured and transparent manner. This demonstrates that the applicability of the framework may even go beyond what it was initially intended for.

Large language models (LLMs) achieve strong performance across many natural language processing tasks, yet their decision processes remain difficult to interpret. This lack of transparency creates challenges for trust, debugging, and deployment in real-world systems. This paper presents an applied comparative study of three explainability techniques: Integrated Gradients, Attention Rollout, and SHAP, on a fine-tuned DistilBERT model for SST-2 sentiment classification. Rather than proposing new methods, the focus is on evaluating the practical behavior of existing approaches under a consistent and reproducible setup. The results show that gradient-based attribution provides more stable and intuitive explanations, while attention-based methods are computationally efficient but less aligned with prediction-relevant features. Model-agnostic approaches offer flexibility but introduce higher computational cost and variability. This work highlights key trade-offs between explainability methods and emphasizes their role as diagnostic tools rather than definitive explanations. The findings provide practical insights for researchers and engineers working with transformer-based NLP systems. T